NEW YORK – The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics said Wednesday that they have entered into a collaborative research partnership aimed at advancing RNA-based molecular signatures for pancreatic cancer disease progression and drug response prediction.
The partners will apply GeneCentric's single patient RNA-based report, including its Pancreatic Cancer Subtype Profiler, PurIST, to PanCAN's extensive collection of patient molecular and outcomes data generated through its scientific and clinical programs.